Drug Profile
D 0160
Latest Information Update: 21 Sep 2000
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antihypertensives; Heart failure therapies
- Mechanism of Action Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 21 Sep 2000 Discontinued-Preclinical for Congestive heart failure in United Kingdom (Unknown route)
- 21 Sep 2000 Discontinued-Preclinical for Hypertension in United Kingdom (Unknown route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed